Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0111

Scientific exchange · Dr. William Abbott

29 Jan 2026 · Phone · Dr. William Abbott, Universitätsklinikum Heidelberg · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0111—

Capture insight from this engagement

Location: Universitätsklinikum Heidelberg
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic
VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Scientific exchange with radiation oncologist at Universitätsklinikum Heidelberg. Discussed chemotherapy-free first line.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 3
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0111

Audit history (0)

All create, update and approval events for this record

No audit events in sample data